14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CSBR vs CODA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Coda Octopus Group, Inc. (CODA) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CSBR carries a Unified Composite Score of 33.4/100 (SELL) at $4.34 (43.4x Forward P/E, -1.5% operating margin), whereas CODA carries 42.3/100 (HOLD) at $7.50 (13.3x Forward P/E, 20.1% operating margin).
Technical & Structure Timing Caution: CSBR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile CODA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CSBR vs CODA. Trailing 12-month operating profitability (CSBR -1.5% vs CODA 20.1%) and valuation multiples (CSBR 43.4x vs CODA 13.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Aerospace & Defense value chain with $89.1M market capitalization and 20.1% operating margin.
OpEx & R&D Reinvestment46.0% of Rev ($13M)
90D Engineering Disclosures0 Published
Investor FAQ CSBR vs CODA Key Questions & Quantitative Answers
As of Nov 20, 2026, Coda Octopus Group, Inc. (CODA) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CSBR carries a Unified Composite Score of 33.4/100 (SELL) at $4.34 (43.4x Forward P/E, -1.5% operating margin), whereas CODA carries 42.3/100 (HOLD) at $7.50 (13.3x Forward P/E, 20.1% operating margin). Technical & Structure Timing Caution: CSBR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile CODA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CODA leads the Growth & Scale pillar: CSBR posts +8.8% YoY revenue growth and -61.1% YoY earnings growth on $61M TTM revenue (49.8% gross margin, -1.5% operating margin), compared with CODA at +9.2% YoY revenue growth and +9.1% YoY earnings growth on $29M TTM revenue (66.1% gross margin, 20.1% operating margin). On trailing 12-month operating scale, CSBR generates $61M in USD-normalized revenue versus $29M for CODA. In operating R&D and SG&A reinvestment, CSBR deploys 51.3% of Rev ($31M) (0 90-day corporate R&D disclosures) versus 46.0% of Rev ($13M) (0 disclosures) for CODA.
CODA screens cheaper on headline valuation multiples. CSBR trades at 43.4x Forward P/E, 22.9x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (0.7% EBITDA margin), whereas CODA trades at 13.3x Forward P/E, 17.9x Trailing P/E, 3.81x PEG, and 2.1x EV/Revenue (20.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CSBR (-28.4% ROE) versus CODA (8.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CSBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 24% Vol realized risk). By comparison, CODA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.